DOT1L and ovarian carcinoma: Wang et al. found that the transcription factor C/EBPβ contributes to increased H3K79 methylation modifications through recruitment of DOT1L, thereby reducing the efficacy of ovarian cancer chemotherapy (Wang et al., 2019).